	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
).	O
•	O
WARNINGS	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
).	O
•	O
WARNINGS	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
).	O
•	O
WARNINGS	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
and	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Meloxicam	B-D000077239
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
(4.2)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
reactions	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)].	O
WARNING:	O
CARDIOVASCULAR	O
and	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Meloxicam	B-D000077239
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4.2,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
higher	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
(5.2)	O
Elevated	O
liver	O
enzymes,	O
and	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen.	O
(5.3)	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment.	O
(5.4)	O
Fluid	O
retention	O
and	O
edema.	O
Should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long-term	O
use.	O
Use	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists.	O
The	O
use	O
of	O
meloxicam	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
is	O
not	O
recommended	O
(5.6)	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning.	O
Discontinue	O
meloxicam	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions.	O
(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years’	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
CONTRAINDICATIONS	O
(4.2)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs,	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
meloxicam,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Patients	B-D010361
and	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
meloxicam	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
This	O
should	O
include	O
discontinuation	O
of	O
meloxicam	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs	O
including	O
meloxicam.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure,	O
some	O
of	O
them	O
with	O
fatal	O
outcomes	O
have	O
been	O
reported	O
[see	O
ADVERSE	O
REACTIONS	O
(6.1)].	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
evaluated	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
meloxicam.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
meloxicam	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.6)	O
AND	O
CLINICAL	O
PHARMACOLOGY	O
(12.3)].	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
meloxicam,	O
can	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
NSAIDs,	O
including	O
meloxicam,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
(BP)	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE	O
inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs.	O
Use	O
meloxicam	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention,	O
hypertension,	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis,	O
renal	O
insufficiency,	O
acute	O
renal	O
failure,	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
and	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
A	O
pharmacokinetic	O
study	O
in	O
patients	O
with	O
mild	O
and	O
moderate	O
renal	O
impairment	O
revealed	O
that	O
no	O
dosage	O
adjustments	O
in	O
these	O
patient	O
populations	O
are	O
required.	O
Patients	B-D010361
with	O
severe	O
renal	O
impairment	O
have	O
not	O
been	O
studied.	O
The	O
use	O
of	O
meloxicam	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
with	O
CrCl	O
less	O
than	O
20	O
mL/min	O
is	O
not	O
recommended.	O
A	O
study	O
performed	O
in	O
patients	O
on	O
hemodialysis	O
revealed	O
that	O
although	O
overall	O
Cmax	O
was	O
diminished	O
in	O
this	O
population,	O
the	O
proportion	O
of	O
free	O
drug	O
not	O
bound	O
to	O
plasma	O
was	O
increased.	O
Therefore	O
it	O
is	O
recommended	O
that	O
meloxicam	O
dosage	O
in	O
this	O
population	O
not	O
exceed	O
7.5	O
mg	O
per	O
day.	O
Closely	O
monitor	O
the	O
renal	O
function	O
of	O
patients	O
with	O
impaired	O
renal	O
function	O
who	O
are	O
taking	O
meloxicam	O
[see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
(2.1),	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.7)	O
AND	O
CLINICAL	O
PHARMACOLOGY	O
(12.3)].	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
meloxicam	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
It	O
is	O
advisable	O
to	O
rehydrate	O
patients	O
first	O
and	O
then	O
start	O
therapy	O
with	O
meloxicam.	O
Caution	O
is	O
also	O
recommended	O
in	O
patients	O
with	O
pre-existing	O
kidney	O
disease.	O
The	O
extent	O
to	O
which	O
metabolites	O
may	O
accumulate	O
in	O
patients	O
with	O
renal	O
impairment	O
has	O
not	O
been	O
studied	O
with	O
meloxicam.	O
Because	O
some	O
meloxicam	O
metabolites	O
are	O
excreted	O
by	O
the	O
kidney,	O
monitor	O
patients	O
with	O
significant	O
renal	O
impairment	O
closely.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
meloxicam.	O
Meloxicam	B-D000077239
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	O
(4.1)	O
AND	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.12)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Adverse	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
avoid	O
the	O
use	O
of	O
meloxicam,	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)	O
AND	O
PATIENT	O
COUNSELING	O
INFORMATION	O
(17.8)].	O
5.10	O
Corticosteroid	O
Treatment	O
Meloxicam	B-D000077239
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
disease	O
exacerbation.	O
Slowly	O
taper	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
meloxicam	O
in	O
reducing	O
fever	O
and	O
inflammation	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
may	O
occur	O
in	O
patients	O
receiving	O
NSAIDs,	O
including	O
meloxicam.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
meloxicam,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
treated	O
with	O
meloxicam	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.13	O
Use	O
in	O
Patients	B-D010361
with	O
Pre-existing	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
meloxicam	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
pre-existing	O
asthma.	O
5.14	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
their	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
or	O
renal	O
disease	O
develop,	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.)	O
or	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
meloxicam	O
should	O
be	O
discontinued.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
(≥5%	O
and	O
greater	O
than	O
placebo)	O
adverse	O
events	O
in	O
adults	O
are	O
diarrhea,	O
upper	O
respiratory	O
tract	O
infections,	O
dyspepsia,	O
and	O
influenza-like	O
symptoms	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Zydus	O
Pharmaceuticals	O
(USA)	O
Inc.	O
at	O
1-877-993-8779	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Cardiovascular	O
thrombotic	O
events	O
[	O
see	O
BOXED	O
WARNINGS	O
AND	O
WARNING	O
AND	O
PRECAUTIONS	O
(5.1)]	O
Gastrointestinal	O
effects	O
[	O
see	O
BOXED	O
WARNING	O
AND	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatic	O
effects	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Congestive	O
heart	O
failure	O
and	O
edema	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
effects	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactoid	O
reaction	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Adverse	O
skin	O
reaction	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Adult	B-D000328
s	O
Osteoarthritis	B-D010003
and	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
The	O
meloxicam	O
Phase	O
2/3	O
clinical	O
trial	O
database	O
includes	O
10,122	O
OA	O
patients	O
and	O
1012	O
RA	O
patients	O
treated	O
with	O
meloxicam	O
7.5	O
mg/day,	O
3,505	O
OA	O
patients	O
and	O
1351	O
RA	O
patients	O
treated	O
with	O
meloxicam	O
15	O
mg/day.	O
Meloxicam	B-D000077239
at	O
these	O
doses	O
was	O
administered	O
to	O
661	O
patients	O
for	O
at	O
least	O
6	O
months	O
and	O
to	O
312	O
patients	O
for	O
at	O
least	O
one	O
year.	O
Approximately	O
10,500	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
osteoarthritis	O
trials	O
and	O
2363	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
rheumatoid	O
arthritis	O
trials.	O
Gastrointestinal	O
(GI)	O
adverse	O
events	O
were	O
the	O
most	O
frequently	O
reported	O
adverse	O
events	O
in	O
all	O
treatment	O
groups	O
across	O
meloxicam	O
trials.	O
A	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
osteoarthritis	O
of	O
the	O
knee	O
or	O
hip	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
meloxicam	O
with	O
placebo	O
and	O
with	O
an	O
active	O
control.	O
Two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
were	O
conducted	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
meloxicam	O
with	O
placebo.	O
Table	O
1a	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
meloxicam	O
treatment	O
groups	O
in	O
a	O
12-week	O
placebo-	O
and	O
active-controlled	O
osteoarthritis	O
trial.	O
Table	O
1b	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
meloxicam	O
treatment	O
groups	O
in	O
two	O
12-week	O
placebo-	O
controlled	O
rheumatoid	O
arthritis	O
trials.	O
Table	O
1aAdverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
Meloxicam	B-D000077239
Patients	B-D010361
in	O
a	O
12-Week	O
Osteoarthritis	B-D010003
Placebo-	O
and	O
Active-Controlled	O
Trial	O
Placebo	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
Diclofenac	B-D004008
100	O
mg	O
daily	O
1WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral	O
and	O
edema	O
legs	O
combined	O
2WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous	O
and	O
rash	O
maculo-papular	O
combined	O
No	O
.	O
of	O
Patients	B-D010361
157	O
154	O
156	O
153	O
Gastrointestinal	O
17.2	O
20.1	O
17.3	O
28.1	O
Abdominal	B-D015746
Pain	I-D015746
2.5	O
1.9	O
2.6	O
1.3	O
Diarrhea	B-D003967
3.8	O
7.8	O
3.2	O
9.2	O
Dyspepsia	B-D004415
4.5	O
4.5	O
4.5	O
6.5	O
Flatulence	B-D005414
4.5	O
3.2	O
3.2	O
3.9	O
Nausea	B-D009325
3.2	O
3.9	O
3.8	O
7.2	O
Body	O
as	O
a	O
Whole	O
Accident	O
Household	O
1.9	O
4.5	O
3.2	O
2.6	O
Edema	B-D004487
1	O
2.5	O
1.9	O
4.5	O
3.3	O
Fall	O
0.6	O
2.6	O
0.0	O
1.3	O
Influenza-Like	O
Symptoms	O
5.1	O
4.5	O
5.8	O
2.6	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
3.2	O
2.6	O
3.8	O
2.0	O
Headache	B-D006261
10.2	O
7.8	O
8.3	O
5.9	O
Respiratory	O
Pharyngitis	B-D010612
1.3	O
0.6	O
3.2	O
1.3	O
Upper	O
Respiratory	O
Tract	O
Infection	O
1.9	O
3.2	O
1.9	O
3.3	O
Skin	B-D012867
Rash2	O
2.5	O
2.6	O
0.6	O
2.0	O
Table	O
1bAdverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
MELOXICAM	O
Patients	B-D010361
in	O
two	O
12-Week	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Placebo	O
Controlled	O
Trials	O
Placebo	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
1MedDRA	O
high	O
level	O
term	O
(preferred	O
terms):	O
dyspeptic	O
signs	O
and	O
symptoms	O
(dyspepsia,	O
dyspepsia	O
aggravated,	O
eructation,	O
gastrointestinal	O
irritation),	O
upper	O
respiratory	O
tract	O
infections-pathogen	O
unspecified	O
(laryngitis	O
NOS,	O
pharyngitis	O
NOS,	O
sinusitis	O
NOS),	O
joint	O
related	O
signs	O
and	O
symptoms	O
(arthralgia,	O
arthralgia	O
aggravated,	O
joint	O
crepitation,	O
joint	O
effusion,	O
joint	O
swelling)	O
2MedDRA	O
preferred	O
term:	O
nausea,	O
abdominal	O
pain	O
NOS,	O
influenza-like	O
illness,	O
headaches	O
NOS,	O
and	O
rash	O
NOS	O
No	O
.	O
of	O
Patients	B-D010361
469	O
481	O
477	O
Gastrointestinal	O
disorders	O
14.1	O
18.9	O
16.8	O
Abdominal	O
pain	O
NOS2	O
0.6	O
2.9	O
2.3	O
Dyspeptic	O
signs	O
and	O
symptoms1	O
3.8	O
5.8	O
4.0	O
Nausea	B-D009325
2	O
2.6	O
3.3	O
3.8	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Influenza	O
like	O
illness2	O
2.1	O
2.9	O
2.3	O
Infection	O
and	O
infestations	O
Upper	O
respiratory	O
tract	O
infections-pathogen	O
class	O
unspecified1	O
4.1	O
7.0	O
6.5	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Joint	O
related	O
signs	O
and	O
symptoms	O
1	O
1.9	O
1.5	O
2.3	O
Nervous	O
system	O
disorders	O
Headache	B-D006261
s	O
NOS2	O
6.4	O
6.4	O
5.5	O
Skin	B-D012867
and	O
subcutaneous	O
tissue	O
disorders	O
Rash	O
NOS2	O
1.7	O
1.0	O
2.1	O
The	O
adverse	O
events	O
that	O
occurred	O
with	O
meloxicam	O
in	O
≥2%	O
of	O
patients	O
treated	O
short-term	O
(4-6	O
weeks)	O
and	O
long-term	O
(6	O
months)	O
in	O
active-controlled	O
osteoarthritis	O
trials	O
are	O
presented	O
in	O
Table	O
2	O
Table	O
2Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
Meloxicam	B-D000077239
Patients	B-D010361
in	O
4	O
to	O
6	O
Weeksand	O
6	O
Month	O
Active-Controlled	O
Osteoarthritis	B-D010003
Trials	O
4	O
-	O
6	O
Weeks	O
Controlled	O
Trials	O
6	O
Month	O
Controlled	O
Trials	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
No	O
.	O
of	O
Patients	B-D010361
8955	O
256	O
169	O
306	O
Gastrointestinal	O
11.8	O
18.0	O
26.6	O
24.2	O
Abdominal	B-D015746
Pain	I-D015746
2.7	O
2.3	O
4.7	O
2.9	O
Constipation	B-D003248
0.8	O
1.2	O
1.8	O
2.6	O
Diarrhea	B-D003967
1.9	O
2.7	O
5.9	O
2.6	O
Dyspepsia	B-D004415
3.8	O
7.4	O
8.9	O
9.5	O
Flatulence	B-D005414
0.5	O
0.4	O
3.0	O
2.6	O
Nausea	B-D009325
2.4	O
4.7	O
4.7	O
7.2	O
Vomiting	B-D014839
0.6	O
0.8	O
1.8	O
2.6	O
Body	O
as	O
a	O
Whole	O
Accident	O
Household	O
0.0	O
0.0	O
0.6	O
2.9	O
Edema	B-D004487
WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral,	O
and	O
edema	O
legs	O
combined	O
0.6	O
2.0	O
2.4	O
1.6	O
Pain	B-D010146
0.9	O
2.0	O
3.6	O
5.2	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
1.1	O
1.6	O
2.4	O
2.6	O
Headache	B-D006261
2.4	O
2.7	O
3.6	O
2.6	O
Hematologic	O
Anemia	B-D000740
0.1	O
0.0	O
4.1	O
2.9	O
Musculoskeletal	O
Arthralgia	B-D018771
0.5	O
0.0	O
5.3	O
1.3	O
Back	B-D001416
Pain	I-D001416
0.5	O
0.4	O
3.0	O
0.7	O
Psychiatric	O
Insomnia	O
0.4	O
0.0	O
3.6	O
1.6	O
Respiratory	O
Cough	B-D003371
ing	O
0.2	O
0.8	O
2.4	O
1.0	O
Upper	O
Respiratory	O
tract	O
Infection	O
0.2	O
0.0	O
8.3	O
7.5	O
Skin	B-D012867
Pruritus	B-D011537
0.4	O
1.2	O
2.4	O
0.0	O
RashWHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	O
and	O
rash	O
maculo-papular	O
combined	O
0.3	O
1.2	O
3.0	O
1.3	O
Urinary	O
Micturition	O
Frequency	O
0.1	O
0.4	O
2.4	O
1.3	O
Urinary	B-D014551
Tract	I-D014551
Infection	O
0.3	O
0.4	O
4.7	O
6.9	O
Higher	O
doses	O
of	O
meloxicam	O
(22.5	O
mg	O
and	O
greater)	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
GI	O
events;	O
therefore,	O
the	O
daily	O
dose	O
of	O
meloxicam	O
should	O
not	O
exceed	O
15	O
mg.	O
The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
drug	O
reactions	O
occurring	O
in	O
<2%	O
of	O
patients	O
receiving	O
meloxicam	O
in	O
clinical	O
trials	O
involving	O
approximately	O
16,200	O
patients.	O
Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
malaise,	O
syncope,	O
weight	O
decrease,	O
weight	O
increase	O
Cardiovascular	O
angina	O
pectoris,	O
cardiac	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
convulsions,	O
paresthesia,	O
tremor,	O
vertigo	O
Gastrointestinal	O
colitis,	O
dry	O
mouth,	O
duodenal	O
ulcer,	O
eructation,	O
esophagitis,	O
gastric	O
ulcer,	O
gastritis,	O
gastroesophageal	O
reflux,	O
gastrointestinal	O
hemorrhage,	O
hematemesis,	O
hemorrhagic	O
duodenal	O
ulcer,	O
hemorrhagic	O
gastric	O
ulcer,	O
intestinal	O
perforation,	O
melena,	O
pancreatitis,	O
perforated	O
duodenal	O
ulcer,	O
perforated	O
gastric	O
ulcer,	O
stomatitis	O
ulcerative	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
arrhythmia,	O
palpitation,	O
tachycardia	O
Hematologic	O
leukopenia,	O
purpura,	O
thrombocytopenia	O
Liver	B-D008099
and	O
Biliary	O
System	O
ALT	O
increased,	O
AST	O
increased,	O
bilirubinemia,	O
GGT	O
increased,	O
hepatitis	O
Metabolic	O
and	O
Nutritional	O
dehydration	O
Psychiatric	O
abnormal	O
dreaming,	O
anxiety,	O
appetite	O
increased,	O
confusion,	O
depression,	O
nervousness,	O
somnolence	O
Respiratory	O
asthma,	O
bronchospasm,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
angioedema,	O
bullous	O
eruption,	O
photosensitivity	O
reaction,	O
pruritus,	O
sweating	O
increased,	O
urticaria	O
Special	O
Senses	O
abnormal	O
vision,	O
conjunctivitis,	O
taste	O
perversion,	O
tinnitus	O
Urinary	O
System	O
albuminuria,	O
BUN	O
increased,	O
creatinine	O
increased,	O
hematuria,	O
renal	O
failure	O
6.2	O
Post	O
Marketing	B-D040541
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
meloxicam.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
about	O
whether	O
to	O
include	O
an	O
adverse	O
event	O
from	O
spontaneous	O
reports	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
event,	O
(2)	O
number	O
of	O
reports,	O
or	O
(3)	O
strength	O
of	O
causal	O
relationship	O
to	O
the	O
drug.	O
Adverse	O
reactions	O
reported	O
in	O
worldwide	O
post	O
marketing	O
experience	O
or	O
the	O
literature	O
include:	O
acute	O
urinary	O
retention;	O
agranulocytosis;	O
alterations	O
in	O
mood	O
(such	O
as	O
mood	O
elevation);	O
anaphylactoid	O
reactions	O
including	O
shock;	O
erythema	O
multiforme;	O
exfoliative	O
dermatitis;	O
interstitial	O
nephritis;	O
jaundice;	O
liver	O
failure;	O
Stevens-Johnson	O
syndrome,	O
and	O
toxic	O
epidermal	O
necrolysis.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
hypersensitivity	O
(5.2)	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.3)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.4)	O
5.1	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	O
associated	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
in	O
patients	O
who	O
have	O
either	O
a	O
known	O
hypersensitivity	O
to	O
aspirin/non-steroidal	O
anti-inflammatory	O
drugs	O
or	O
a	O
past	O
medical	O
history	O
of	O
asthma.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.4	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
Ketorolac	B-D020910
tromethamine	O
ophthalmic	O
solution	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
the	O
labeling:	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Cornea	B-D003315
l	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
1	O
-	O
5%	O
of	O
patients	O
included	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema	O
and	O
ocular	O
pain.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-678-1605	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
occurring	O
in	O
approximately	O
1	O
to	O
5%	O
of	O
the	O
overall	O
study	O
population	O
were	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema,	O
and	O
ocular	O
pain.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
These	O
reactions	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
patients	O
participating	O
in	O
clinical	O
trials.	O
Other	O
adverse	O
reactions	O
occurring	O
approximately	O
in	O
1	O
to	O
10%	O
of	O
the	O
time	O
during	O
treatment	O
with	O
other	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included	O
allergic	O
reactions,	O
corneal	O
edema,	O
iritis,	O
ocular	O
inflammation,	O
ocular	O
irritation,	O
superficial	O
keratitis,	O
and	O
superficial	O
ocular	O
infections.	O
Other	O
adverse	O
reactions	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included:	O
corneal	O
ulcer,	O
eye	O
dryness,	O
and	O
visual	O
disturbance	O
(blurry	O
vision).	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma,	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning	O
and	O
corneal	O
melt,	O
and	O
epithelial	O
breakdown	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.4	O
)].	O
CARDIOVASCULAR	O
RISK	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
s	O
ee	O
WARNINGS	O
).	O
Naproxen	B-D009288
as	O
NAPRELAN	O
®	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
s	O
ee	O
WARNINGS	O
).	O
GASTROINTESTINAL	O
RISK	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
people	O
are	O
at	O
greater	O
risk	O
for	O
ser	O
i	O
ous	O
gastrointestinal	O
events.	O
(	O
s	O
ee	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
NAPRELAN®	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
NAPRELAN®	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®***	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
NAPRELAN®	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
-	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
INCIDENCE	O
GREATER	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(CAUSAL	O
RELATIONSHIP	O
UNKNOWN)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Sumatriptan	B-D018170
And	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Cardiovascular	O
Thrombotic	O
Events:	O
Perform	O
cardiac	O
evaluation	O
in	O
patients	O
with	O
cardiovascular	O
risk	O
factors.	O
(5.1)	O
Arrhythmias:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.3)	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure:	O
Generally	O
not	O
associated	O
with	O
myocardial	O
ischemia;	O
evaluate	O
for	O
coronary	O
artery	O
disease	O
in	O
patients	O
at	O
high	O
risk.	O
(5.4)	O
Cerebrovascular	O
Events:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.5)	O
Other	O
Vasospasm	O
Reactions:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
non-coronary	O
vasospastic	O
reaction	O
occurs.	O
(5.6)	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.7)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.8)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.9)	O
Medication	O
Overuse	O
Headache	B-D006261
:	O
Detoxification	O
may	O
be	O
necessary.	O
(5.10)	O
Serotonin	B-D020230
Syndrome	I-D020230
:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.11)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
(5.12)	O
Anaphylactic	O
Reactions:	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
Seep	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.(5.13)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
at	O
first	O
sign	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.14)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.16)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.17)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
The	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
ischemic	O
or	O
vasospastic	O
coronary	O
artery	O
disease	O
(CAD)	O
and	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
due	O
to	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
events	O
with	O
sumatriptan	O
and	O
NSAIDS	O
[see	O
Contraindications	B-D000075202
(4)].	O
Cardiovascular	O
Events	O
with	O
Sumatriptan	B-D018170
There	O
have	O
been	O
rare	O
reports	O
of	O
serious	O
cardiac	O
adverse	O
reactions,	O
including	O
acute	O
myocardial	O
infarction,	O
occurring	O
within	O
a	O
few	O
hours	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
of	O
these	O
reactions	O
occurred	O
in	O
patients	O
without	O
known	O
CAD.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
cause	O
coronary	O
artery	O
vasospasm	O
(Prinzmetal's	O
angina),	O
even	O
in	O
patients	O
without	O
a	O
history	O
of	O
CAD.	O
Cardiovascular	O
Thrombotic	O
Events	O
with	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Perform	O
a	O
cardiovascular	O
evaluation	O
in	O
patients	O
who	O
have	O
multiple	O
cardiovascular	O
risk	O
factors	O
(e.g.,	O
increased	O
age,	O
diabetes,	O
hypertension,	O
smoking,	O
obesity,	O
strong	O
family	O
history	O
of	O
CAD)	O
prior	O
to	O
receiving	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
If	O
there	O
is	O
evidence	O
of	O
CAD	O
or	O
coronary	O
artery	O
vasospasm,	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated.	O
For	O
patients	O
with	O
multiple	O
cardiovascular	O
risk	O
factors	O
who	O
have	O
a	O
negative	O
cardiovascular	O
evaluation,	O
consider	O
administering	O
the	O
first	O
dose	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
a	O
medically	O
supervised	O
setting	O
and	O
performing	O
an	O
electrocardiogram	O
(ECG)	O
immediately	O
following	O
administration	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
For	O
such	O
patients,	O
consider	O
periodic	O
cardiovascular	O
evaluation	O
in	O
intermittent	O
long-term	O
users	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
cardiovascular	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
cardiovascular	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
cardiovascular	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
cause	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
1	O
in	O
5	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
gastrointestinal	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
gastrointestinal	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
appear	O
to	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
daily	O
for	O
3	O
to	O
6	O
months	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
1	O
year.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Among	O
3,302	O
adult	O
patients	O
with	O
migraine	O
who	O
received	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials,	O
1	O
patient	O
experienced	O
a	O
recurrence	O
of	O
gastric	O
ulcer	O
after	O
taking	O
8	O
doses	O
over	O
3	O
weeks,	O
and	O
1	O
patient	O
developed	O
a	O
gastric	O
ulcer	O
after	O
treating	O
an	O
average	O
of	O
8	O
attacks	O
per	O
month	O
over	O
7	O
months.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
gastrointestinal	O
bleeding	O
compared	O
with	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
gastrointestinal	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
gastrointestinal	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients,	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
high	O
risk	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Arrhythmias	O
Life	B-D019369
-threatening	O
disturbances	O
of	O
cardiac	O
rhythm,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
leading	O
to	O
death,	O
have	O
been	O
reported	O
within	O
a	O
few	O
hours	O
following	O
the	O
administration	O
of	O
5-HT1	O
agonists.	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
these	O
disturbances	O
occur.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
Wolff-Parkinson-White	O
syndrome	O
or	O
arrhythmias	O
associated	O
with	O
other	O
cardiac	O
accessory	O
conduction	O
pathway	O
disorders.	O
5.4	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
Sensation	B-D012677
s	O
of	O
tightness,	O
pain,	O
pressure,	O
and	O
heaviness	O
in	O
the	O
precordium,	O
throat,	O
neck,	O
and	O
jaw	O
commonly	O
occur	O
after	O
treatment	O
with	O
sumatriptan	O
and	O
are	O
usually	O
non-cardiac	O
in	O
origin.	O
However,	O
perform	O
a	O
cardiac	O
evaluation	O
if	O
these	O
patients	O
are	O
at	O
high	O
cardiac	O
risk.	O
The	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
is	O
contraindicated	O
in	O
patients	O
with	O
CAD	O
and	O
those	O
with	O
Prinzmetal's	B-C536421
variant	I-C536421
angina	I-C536421
.	O
5.5	O
Cerebrovascular	O
Events	O
Cerebral	O
hemorrhage,	O
subarachnoid	O
hemorrhage,	O
and	O
stroke	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
and	O
some	O
have	O
resulted	O
in	O
fatalities.	O
In	O
a	O
number	O
of	O
cases,	O
it	O
appears	O
possible	O
that	O
the	O
cerebrovascular	O
events	O
were	O
primary,	O
the	O
5-HT1	O
agonist	O
having	O
been	O
administered	O
in	O
the	O
incorrect	O
belief	O
that	O
the	O
symptoms	O
experienced	O
were	O
a	O
consequence	O
of	O
migraine	O
when	O
they	O
were	O
not.	O
Also,	O
patients	O
with	O
migraine	O
may	O
be	O
at	O
increased	O
risk	O
of	O
certain	O
cerebrovascular	O
events	O
(e.g.,	O
stroke,	O
hemorrhage,	O
TIA).	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
a	O
cerebrovascular	O
event	O
occurs.	O
Before	O
treating	O
headaches	O
in	O
patients	O
not	O
previously	O
diagnosed	O
as	O
migraineurs,	O
and	O
in	O
migraineurs	O
who	O
present	O
with	O
atypical	O
symptoms,	O
exclude	O
other	O
potentially	O
serious	O
neurological	O
conditions.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
stroke	O
or	O
TIA	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.6	O
Other	O
Vasospasm	O
Reactions	O
Sumatriptan	B-D018170
may	O
cause	O
non-coronary	O
vasospastic	O
reactions,	O
such	O
as	O
peripheral	O
vascular	O
ischemia,	O
gastrointestinal	O
vascular	O
ischemia	O
and	O
infarction	O
(presenting	O
with	O
abdominal	O
pain	O
and	O
bloody	O
diarrhea),	O
splenic	O
infarction,	O
and	O
Raynaud′s	O
syndrome.	O
In	O
patients	O
who	O
experience	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
non-coronary	O
vasospasm	O
reaction	O
following	O
the	O
use	O
of	O
any	O
5-HT1	O
agonist,	O
rule	O
out	O
a	O
vasospastic	O
reaction	O
before	O
receiving	O
additional	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Reports	O
of	O
transient	O
and	O
permanent	O
blindness	O
and	O
significant	O
partial	O
vision	O
loss	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
5-HT1	O
agonists.	O
Since	O
visual	O
disorders	O
may	O
be	O
part	O
of	O
a	O
migraine	O
attack,	O
a	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
use	O
of	O
5-HT1	O
agonists	O
have	O
not	O
been	O
clearly	O
established.	O
5.7	O
Hepatotoxicity	O
Borderline	O
elevations	O
of	O
1	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
who	O
take	O
NSAIDs	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Hepatic	O
abnormalities	O
may	O
be	O
the	O
result	O
of	O
hypersensitivity	O
rather	O
than	O
direct	O
toxicity.	O
These	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
essentially	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Notable	O
(3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
elevations	O
of	O
SGPT	O
(ALT)	O
or	O
SGOT	O
(AST)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
with	O
NSAIDs.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.7),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
evaluated	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
or	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.8	O
Hypertension	B-D006973
Significant	O
elevation	O
in	O
blood	O
pressure,	O
including	O
hypertensive	O
crisis	O
with	O
acute	O
impairment	O
of	O
organ	O
systems,	O
has	O
been	O
reported	O
on	O
rare	O
occasions	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
including	O
sumatriptan,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
This	O
occurrence	O
has	O
included	O
patients	O
without	O
a	O
history	O
of	O
hypertension.	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
can	O
also	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
angiotensin	O
receptor	O
blockers	O
(ARBs),	O
beta-blockers,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
in	O
patients	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
uncontrolled	O
hypertension	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.9	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
Since	O
each	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg	O
tablet	O
contain	O
approximately	O
60	O
mg	O
of	O
sodium	O
and	O
each	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
10/60	O
mg	O
tablet	O
contain	O
approximately	O
20	O
mg	O
of	O
sodium,	O
this	O
should	O
be	O
considered	O
in	O
patients	O
whose	O
overall	O
intake	O
of	O
sodium	O
must	O
be	O
severely	O
restricted.	O
5.10	O
Medication	O
Overuse	O
Headache	B-D006261
Overuse	O
of	O
acute	O
migraine	O
drugs	O
(e.g.,	O
ergotamine,	O
triptans,	O
opioids,	O
or	O
a	O
combination	O
of	O
these	O
drugs	O
for	O
10	O
or	O
more	O
days	O
per	O
month)	O
may	O
lead	O
to	O
exacerbation	O
of	O
headache	O
(medication	O
overuse	O
headache).	O
Medication	O
overuse	O
headache	O
may	O
present	O
as	O
migraine-like	O
daily	O
headaches,	O
or	O
as	O
a	O
marked	O
increase	O
in	O
frequency	O
of	O
migraine	O
attacks.	O
Detoxification	O
of	O
patients,	O
including	O
withdrawal	O
of	O
the	O
overused	O
drugs,	O
and	O
treatment	O
of	O
withdrawal	O
symptoms	O
(which	O
often	O
includes	O
a	O
transient	O
worsening	O
of	O
headache)	O
may	O
be	O
necessary.	O
5.11	O
Serotonin	B-D020230
Syndrome	I-D020230
Serotonin	B-D012701
syndrome	O
may	O
occur	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
particularly	O
during	O
coadministration	O
with	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs),	O
tricyclic	O
antidepressants	O
(TCAs),	O
and	O
MAO	O
inhibitors	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Drug	B-D004347
Interactions	I-D004347
(7.1)].	O
Serotonin	B-D012701
syndrome	O
symptoms	O
may	O
include	O
mental	O
status	O
changes	O
(e.g.,	O
agitation,	O
hallucinations,	O
coma),	O
autonomic	O
instability	O
(e.g.,	O
tachycardia,	O
labile	O
blood	O
pressure,	O
hyperthermia),	O
neuromuscular	O
aberrations	O
(e.g.,	O
hyperreflexia,	O
incoordination),	O
and/or	O
gastrointestinal	O
symptoms	O
(e.g.,	O
nausea,	O
vomiting,	O
diarrhea).	O
The	O
onset	O
of	O
symptoms	O
usually	O
occurs	O
within	O
minutes	O
to	O
hours	O
of	O
receiving	O
a	O
new	O
or	O
a	O
greater	O
dose	O
of	O
a	O
serotonergic	O
medication.	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
serotonin	O
syndrome	O
is	O
suspected.	O
5.12	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
salt	O
depletion,	O
those	O
taking	O
diuretics	O
and	O
angiotensin-converting	O
enzyme	O
(ACE)	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
renal	O
disease	O
develop	O
or	O
if	O
systemic	O
manifestations	O
occur.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(creatinine	O
clearance	O
[CrCl]	O
<30	O
mL/min)	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
mild	O
(CrCl	O
=	O
60	O
to	O
89	O
mL/min)	O
or	O
moderate	O
(CrCl	O
=	O
30	O
to	O
59	O
mL/min)	O
renal	O
impairment,	O
preexisting	O
kidney	O
disease,	O
or	O
dehydration.	O
The	O
renal	O
effects	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.13	O
Anaphylactic	O
Reactions	O
Anaphylactic	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
either	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Such	O
reactions	O
can	O
be	O
life-threatening	O
or	O
fatal.	O
In	O
general,	O
anaphylactic	O
reactions	O
to	O
drugs	O
are	O
more	O
likely	O
to	O
occur	O
in	O
individuals	O
with	O
a	O
history	O
of	O
sensitivity	O
to	O
multiple	O
allergens	O
although	O
anaphylactic	O
reactions	O
with	O
naproxen	O
have	O
occurred	O
in	O
patient	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
or	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
patients	O
with	O
asthma	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reaction	O
to	O
sumatriptan,	O
naproxen,	O
or	O
any	O
other	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.14	O
Serious	O
Skin	B-D012867
Reactions	O
NSAID-containing	O
products	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.15	O
Prema	B-C070504
ture	O
Closure	O
of	O
the	O
Ductus	B-D004373
Arteriosus	I-D004373
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Contraindications	B-D000075202
(4),	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.16	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
gastrointestinal	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
has	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.17	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.18	O
Seizures	B-D012640
Seizures	B-D012640
have	O
been	O
reported	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
have	O
occurred	O
in	O
patients	O
with	O
either	O
a	O
history	O
of	O
seizures	O
or	O
concurrent	O
conditions	O
predisposing	O
to	O
seizures.	O
There	O
are	O
also	O
reports	O
in	O
patients	O
where	O
no	O
such	O
predisposing	O
factors	O
are	O
apparent.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
epilepsy	O
or	O
conditions	O
associated	O
with	O
a	O
lowered	O
seizure	O
threshold.	O
5.19	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.20	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.7,	O
5.12)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Arrhythmias	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Cerebrovascular	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Other	O
Vasospasm	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.8)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Medication	O
Overuse	O
Headache	B-D006261
[see	O
Warnings	O
and	O
Precautions	O
(5.10)]	O
Serotonin	B-D020230
Syndrome	I-D020230
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.12)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Hematological	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.16)]	O
Exacerbation	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
were:	O
Adult	B-D000328
s:	O
Dizziness	B-D004244
,	O
somnolence,	O
nausea,	O
chest	O
discomfort/chest	O
pain,	O
neck/throat/jaw	O
pain/tightness/pressure,	O
paresthesia,	O
dyspepsia,	O
dry	O
mouth.	O
(6.1)	O
Pediatrics	B-D010372
:	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
and	O
muscle	O
tightness.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Macoven	O
at	O
1-800-793-2145	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adult	B-D000328
s	O
The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
clinical	O
trials	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg.	O
See	O
also	O
the	O
full	O
prescribing	O
information	O
for	O
naproxen	O
and	O
sumatriptan	O
products.	O
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
2	O
placebo-controlled	O
clinical	O
trials	O
(Study	O
1	O
and	O
2)	O
in	O
adult	O
patients	O
who	O
received	O
1	O
dose	O
of	O
study	O
drug.	O
Only	O
adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
in	O
any	O
group	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg	O
and	O
that	O
occurred	O
at	O
a	O
frequency	O
greater	O
than	O
the	O
placebo	O
group	O
are	O
included	O
in	O
Table	O
1.	O
Table	O
1.	O
Adverse	O
Reactions	O
in	O
Pooled	O
Placebo-Controlled	O
Trials	O
in	O
Adult	B-D000328
Patients	B-D010361
with	O
Migraine	O
Adverse	O
Reactions	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg%(n	O
=	O
737)	O
Placebo%(n	O
=	O
752)	O
Sumatriptan	B-D018170
85	O
mg%(n	O
=	O
735)	O
Naproxen	B-D009288
Sodium	B-D012964
500	O
mg%(n	O
=	O
732)	O
Nervous	O
system	O
disorders	O
Dizziness	B-D004244
4	O
2	O
2	O
2	O
Somnolence	O
3	O
2	O
2	O
2	O
Paresthesia	B-D010292
2	O
<1	O
2	O
<1	O
Gastrointestinal	O
disorders	O
Nausea	B-D009325
3	O
1	O
3	O
<1	O
Dyspepsia	B-D004415
2	O
1	O
2	O
1	O
Dry	O
mouth	O
2	O
1	O
2	O
<1	O
Pain	B-D010146
and	O
other	O
pressure	O
sensations	O
Chest	O
discomfort/chest	O
pain	O
3	O
<1	O
2	O
1	O
Neck	B-D009333
/throat/jaw	O
pain/tightness/pressure	O
3	O
1	O
3	O
1	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
controlled	O
clinical	O
trials	O
was	O
not	O
affected	O
by	O
gender	O
or	O
age	O
of	O
the	O
patients.	O
There	O
were	O
insufficient	O
data	O
to	O
assess	O
the	O
impact	O
of	O
race	O
on	O
the	O
incidence	O
of	O
adverse	O
reactions.	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
In	O
a	O
placebo-controlled	O
clinical	O
trial	O
that	O
evaluated	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
who	O
received	O
1	O
dose	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
10/60	O
mg,	O
30/180	O
mg,	O
or	O
85/500	O
mg,	O
adverse	O
reactions	O
occurred	O
in	O
13%	O
of	O
patients	O
who	O
received	O
10/60	O
mg,	O
9%	O
of	O
patients	O
who	O
received	O
30/180	O
mg,	O
13%	O
who	O
received	O
85/500	O
mg,	O
and	O
8%	O
who	O
received	O
placebo.	O
No	O
patients	O
who	O
received	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
experienced	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
from	O
the	O
trial.	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
was	O
comparable	O
across	O
all	O
3	O
doses	O
compared	O
with	O
placebo.	O
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
a	O
placebo-controlled	O
trial	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
and	O
were	O
more	O
frequent	O
than	O
the	O
placebo	O
group.	O
Table	O
2.	O
Adverse	O
Reactions	O
in	O
a	O
Placebo-Controlled	O
Trial	O
in	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
with	O
Migraine	O
Adverse	O
Reactions	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
S	B-C012009
10	I-C012009
/60	O
mg%	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
30/180	O
mg%	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg%	O
Placebo%	O
(n	O
=	O
96)	O
(n	O
=	O
97)	O
(n	O
=	O
152)	O
(n	O
=	O
145)	O
Vascular	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
0	O
2	O
<1	O
0	O
Musculoskeletal	O
Muscle	O
tightness	O
0	O
0	O
2	O
0	O
ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
was	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
with	O
600	O
mg	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
whole:	O
Abdominal	O
pain*,	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%),	O
Infection*,	O
Pain	B-D010146
.	O
Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive:	O
Anorexia	B-D000855
,	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
,	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
,	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(12%),	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*.	O
Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses:	O
Tinnitus	B-D014012
.	O
Urogenital:	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction.	O
Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive:	O
Chalky	O
stool;	O
“Clenching	O
teeth”;	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease.	O
Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital:	O
Cystitis	B-D003556
,	O
Glyosuria;	O
Impotence,	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
•	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
ASCOMP	O
with	O
CODEINE	O
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
ASCOMP	O
with	O
CODEINE,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1	O
)].	O
•	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
educations	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
•	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
•	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
•	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
•	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety.	O
•	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
ASCOMP	O
with	O
CODEINE.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
ASCOMP	O
with	O
CODEINE	O
or	O
following	O
a	O
dose	O
increase	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
•	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
ASCOMP	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
ASCOMP	O
with	O
CODEINE	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
•	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
